Fresh From US FDA's Chief Counsel Office, Beth Weinman Talks Qui Tam And Compliance
Executive Summary
Beth Weinman, a former enforcement lawyer in US FDA’s Office of Chief Counsel, recently joined the life sciences and FDA regulatory practice at Ropes & Gray. She spoke with Medtech Insight about whistleblower suits and FDA enforcement priorities.
You may also be interested in...
Top FDA Officials Warn About Non-Vetted Pharmacogenetic Tests After Latest 23andMe Approval
A day after 23andMe gained US FDA go-ahead for a DTC genetic test service to inform patients about their ability to metabolize medications, the agency issued a safety communication, paired with a joint statement from device- and drug-center heads, warning consumers against trusting genetic tests that have not been vetted by FDA.
Watchdog Calls On FDA To Set Policy For Use Of Unauthorized Tests In Public Health Emergencies
The US Government Accountability Office reviewed how the FDA reviewed and monitored COVID-19 tests during the pandemic and found room for improvement. One particular concern was the lack of a straightforward policy on when enforcement discretion would be used.
FDA Allows 510(k)s For HIV Diagnostics
The tests are being moved to class II, special controls, after the agency determined that would be enough to ensure device safety and efficacy.